var title_f43_11_44208="Rectal ultrasound transducer with needle guide";
var content_f43_11_44208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Rectal ultrasound transducer with needle guide",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 618px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle guide is attached directly to the transrectal ultrasound transducer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of RN Alheid.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44208=[""].join("\n");
var outline_f43_11_44208=null;
var title_f43_11_44209="Echo restrictive cardiomyopathy";
var content_f43_11_44209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiography of restrictive cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The echocardiographic features typical of an idiopathic restrictive cardiomyopathy include a nondilated, nonhypertrophied ventricle with dilated atria. Panel A shows the left parasternal long axis view and panel B is a r apical four chamber view.",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle; AO: aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Naser Ammash, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44209=[""].join("\n");
var outline_f43_11_44209=null;
var title_f43_11_44210="The common cold in adults";
var content_f43_11_44210=[" <h1 id=\"patTopicTitle\">",
"  Patient information: The common cold in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/11/44210/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44210/contributors\" id=\"au2060\">",
"       Daniel J Sexton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/11/44210/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44210/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/11/44210/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44210/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/11/44210?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COMMON COLD OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The common cold is one of the most frequent illnesses in the United States. Although most colds are mild and resolve within a short time period, colds cost billions of dollars per year, mostly due to lost time at work and school.",
"    </p>",
"    <p>",
"     This article discusses the common cold in adults. Colds in children are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"      \"Patient information: The common cold in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      COMMON COLD CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The common cold is a group of symptoms caused by one of a large number of viruses. Rhinoviruses cause the greatest number of colds; there are more than 100 different varieties of rhinovirus. Most viruses cause a person to be ill only once. However, due to the large number of viruses, a person can have a cold multiple times throughout his or her lifetime. The average adult experiences two to three colds per year, while children average 8 to 12 colds per year. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"      \"Patient information: The common cold in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Colds are transmitted from person-to-person. Less often, the virus can be transmitted by touching a surface.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Direct contact",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with colds typically carry the cold virus on their hands. The virus may remain alive on the skin and capable of infecting another person for at least two hours. Thus, if a sick person shakes someone's hand and that individual then touches his eye, nose, or mouth, the virus can be transmitted and later infect that person.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Infection from particles on surfaces",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some cold viruses can live on surfaces (such as a counter top, door handle, or phone) for several hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Inhaling viral particles",
"     </span>",
"     &nbsp;&mdash;&nbsp;Droplets containing viral particles can be breathed, coughed, or sneezed into the air by a person with a cold. The virus can be transmitted to others if another person is standing close (a few feet) and the droplet touches that person&rsquo;s eye, nose, or mouth. Covering the mouth while coughing or sneezing reduces this risk. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Prevention'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Most cold viruses are",
"     <strong>",
"      not",
"     </strong>",
"     spread by saliva. Thus, kissing itself is not likely to transmit the common cold, but close direct contact can. Colds are",
"     <strong>",
"      not",
"     </strong>",
"     caused by cold climates or being exposed to cold air. However, some types of virus cause more colds during certain seasons (eg, fall and winter versus spring).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      COMMON COLD SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The common cold usually causes nasal congestion, runny nose, and sneezing. A sore throat may be present on the first day but usually resolves quickly. If a cough occurs, it generally develops on about the fourth or fifth day of symptoms, typically when congestion and runny nose are usually resolving. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36082?source=see_link\">",
"      \"Patient information: Sore throat in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      COMMON COLD COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     In most cases, colds do not cause serious illness. Most colds last for three to seven days, although many people continue to have symptoms (coughing, sneezing, congestion) for up to two weeks.",
"    </p>",
"    <p>",
"     Some viruses that cause the common cold can also depress the immune system or cause swelling in the lining of the nose or airways; this can, in turn, lead to a new viral infection or bacterial infection.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One of the more common complications is sinusitis, which is usually caused by viruses and rarely (about 2 percent of the time) by bacteria. However, it can be difficult to distinguish bacterial sinusitis from sinusitis caused by a cold because the signs and symptoms can be similar (",
"       <a class=\"graphic graphic_table graphicRef58671 \" href=\"mobipreview.htm?0/10/170\">",
"        table 1",
"       </a>",
"       ). Having thick or yellow to green-colored nasal discharge does not mean that bacterial sinusitis has developed; discolored nasal discharge is a normal phase of the common cold. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/13/37073?source=see_link\">",
"        \"Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Lower respiratory infections, such as pneumonia or bronchitis, may develop following a cold. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/57/9106?source=see_link\">",
"        \"Patient information: Acute bronchitis in adults (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"        \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Infection of the middle ear, or otitis media, can accompany or follow a cold. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"        \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The influenza virus, which causes the flu, can also cause features similar to those of a cold (",
"       <a class=\"graphic graphic_table graphicRef56899 \" href=\"mobipreview.htm?34/27/35260\">",
"        table 2",
"       </a>",
"       ). However, the flu usually causes other signs and symptoms (fever, body aches) and is more serious than a cold. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"        \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      COMMON COLD TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no specific treatment for the viruses that cause the common cold. Most treatments are aimed at relieving some of the symptoms of the cold, but do not shorten or cure the cold. Antibiotics are",
"     <strong>",
"      not",
"     </strong>",
"     useful for treating the common cold; antibiotics are only used to treat illnesses caused by bacteria, not viruses.",
"    </p>",
"    <p>",
"     The symptoms of a cold will resolve over time, even without any treatment. The following are treatments that may reduce the symptoms caused by the common cold. People with underlying medical conditions and those who use other over-the-counter or prescription medications should speak with their healthcare provider or pharmacist to ensure that it is safe to use these treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Runny nose and nasal congestion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Runny nose and congestion may improve with the use of decongestants. Pseudoephedrine is a decongestant that can improve nasal congestion. Most drugstores in the United States carry pseudoephedrine behind the counter, so it must be requested from the pharmacist (a prescription is not required).",
"    </p>",
"    <p>",
"     Antihistamines such as diphenhydramine (Benadryl&reg;) may also help, but can cause side effects such as drowsiness and drying of the eyes, nose, and mouth.",
"    </p>",
"    <p>",
"     Nasal inhalers, including ipratropium bromide (Atrovent&reg;, available by prescription) may relieve runny nose and sneezing while cromolyn sodium (NasalCrom&reg;, a non-prescription medicine) may relieve runny nose, cough, and sneezing.",
"    </p>",
"    <p>",
"     Other nasal sprays such an oxymetazoline (Afrin&reg; and others) can also give temporary relief of nasal congestion. However, these sprays should never be used for more than two to three days; use for more than three days use can worsen congestion. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link&amp;anchor=H18#H18\">",
"      \"Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)\", section on 'Rhinitis medicamentosa'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Sore throat and headache",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sore throat and headache are best treated with a mild pain reliever such as acetaminophen (Tylenol&reg;) or a non-steroidal anti-inflammatory agent such as ibuprofen or naproxen (Motrin&reg; or Aleve&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Cough",
"     </span>",
"     &nbsp;&mdash;&nbsp;Common cough medicine ingredients include guaifenesin and dextromethorphan; these are often combined with other medications in over-the-counter cold formulas. However, the benefit of cough medicines is likely to be small to non-existent. In clinical trials, cough suppressants were no more effective in reducing the duration or severity of coughing due to cold than a placebo (a non-drug substitute).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics should",
"     <strong>",
"      not",
"     </strong>",
"     be used to treat an uncomplicated common cold. As noted above, colds are caused by viruses. Antibiotics treat bacterial, not viral infections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Alternative treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heated, humidified air can improve symptoms of nasal congestion and runny nose, and causes few to no side effects.",
"    </p>",
"    <p>",
"     A number of alternative products, including vitamin C and herbal products such as echinacea, are advertised to treat or prevent the common cold. While none of these treatments is likely to cause harm, none has been proven to be effective in clinical trials; their use is not recommended. Certain products, such as nasal gels that contain zinc (eg, Zicam&reg;), have been associated with a permanent loss of smell.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Hand washing is an essential and highly effective way to prevent the spread of infection. Hands should be wet with water and plain soap, and rubbed together for 15 to 30 seconds. Special attention should be paid to the fingernails, between the fingers, and the wrists. Hands should be rinsed thoroughly, and dried with a single use towel.",
"    </p>",
"    <p>",
"     Alcohol-based hand rubs are a good alternative for disinfecting hands if a sink is not available. Hand rubs should be spread over the entire surface of hands, fingers, and wrists until dry, and may be used several times. These rubs can be used repeatedly without skin irritation or loss of effectiveness. Hand rubs are available as a liquid or wipe in small, portable sizes that are easy to carry in a pocket or handbag. When a sink is available, visibly soiled hands should be washed with soap and water.",
"    </p>",
"    <p>",
"     Hands should be washed before preparing food and eating and after coughing, blowing the nose, or sneezing. While it is not always possible to limit contact with people who may be infected with a cold, touching the eyes, nose, or mouth after direct contact should be avoided when possible.",
"    </p>",
"    <p>",
"     In addition, tissues should be used to cover the mouth when sneezing or coughing. These used tissues should be disposed of promptly.",
"     <span class=\"nowrap\">",
"      Sneezing/coughing",
"     </span>",
"     into the sleeve of one's clothing (at the inner elbow) is another means of containing sprays of saliva and secretions and does not contaminate the hands.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The average adult experiences two to three colds per year, while children average 8 to 12 colds per year.",
"      </li>",
"      <li>",
"       Symptoms of the common cold usually include nasal congestion, runny nose, and sneezing. They typically last for three to seven days, although many people have symptoms (coughing, sneezing, congestion) for up to two weeks.",
"      </li>",
"      <li>",
"       People with colds typically carry the cold virus on their hands, where it can infect another person for at least two hours. Some cold viruses can live on surfaces (such as a counter top, door handle, or phone) for several hours. Droplets containing viral particles can be breathed, coughed, or sneezed into the air.",
"      </li>",
"      <li>",
"       There is no specific treatment for colds. Treatment may reduce some of the symptoms of the cold, but do not shorten or cure the cold. Antibiotics are",
"       <strong>",
"        not",
"       </strong>",
"       useful for treating the common cold.",
"      </li>",
"      <li>",
"       Hand washing can prevent the spread of infection. Hands should be wet with water and plain soap, and rubbed together for 15 to 30 seconds. Alcohol-based hand rubs are a good alternative for disinfecting hands if a sink is not available.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287366794\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394885\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=see_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/28/24002?source=see_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/45/25298?source=see_link\">",
"      Patient information: Eustachian tube problems (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/42/4770?source=see_link\">",
"      Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394917\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36082?source=see_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/13/37073?source=see_link\">",
"      Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/57/9106?source=see_link\">",
"      Patient information: Acute bronchitis in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link\">",
"      Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29289?source=see_link\">",
"      Acute bronchitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23542?source=see_link\">",
"      Clinical use of echinacea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41176?source=see_link\">",
"      Coronaviruses",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19383?source=see_link\">",
"      Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/55/24440?source=see_link\">",
"      The common cold in adults: Diagnosis and clinical features",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/commoncold.html\">",
"      www.nlm.nih.gov/medlineplus/commoncold.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/commonCold/\">",
"      www3.niaid.nih.gov/topics/commonCold/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/lung-disease/influenza/in-depth-resources/cold-and-flu-guidelines.html\">",
"      file://www.lungusa.org/lung-disease/influenza/in-depth-resources/cold-and-flu-guidelines.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/11/44210/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/11/44210?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44210/abstract/1\">",
"      Kirkpatrick GL. The common cold. Prim Care 1996; 23:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44210/abstract/2\">",
"      Gwaltney JM Jr, Moskalski PB, Hendley JO. Hand-to-hand transmission of rhinovirus colds. Ann Intern Med 1978; 88:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44210/abstract/3\">",
"      Hendley JO, Gwaltney JM Jr. Mechanisms of transmission of rhinovirus infections. Epidemiol Rev 1988; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44210/abstract/4\">",
"      Turner RB. Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 1997; 78:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44210/abstract/5\">",
"      Turner RB, Cetnarowski WE. Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. Clin Infect Dis 2000; 31:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44210/abstract/6\">",
"      Grimm W, M&uuml;ller HH. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 1999; 106:138.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f43_11_44210=[""].join("\n");
var outline_f43_11_44210=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COMMON COLD OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           COMMON COLD CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           COMMON COLD SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           COMMON COLD COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           COMMON COLD TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/10/170\" title=\"table 1\">",
"           Sinusitis features",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/27/35260\" title=\"table 2\">",
"           Influenza symptoms PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f43_11_44211="Bullous pemphigoid vulva2";
var content_f43_11_44211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44211=[""].join("\n");
var outline_f43_11_44211=null;
var title_f43_11_44212="Sjgrens syndrome";
var content_f43_11_44212=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sjgrens syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/11/44212/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44212/contributors\" id=\"au4425\">",
"       Robert Fox, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/11/44212/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44212/contributors\" id=\"se5724\">",
"       Peter H Schur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/11/44212/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44212/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/11/44212?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SJ&Ouml;GREN'S SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Sj&ouml;gren&rsquo;s syndrome (SS) is a chronic disease in which the body&rsquo;s immune system mistakenly attacks glands that produce moisture in the eyes, the mouth, and elsewhere in the body. The most common symptoms of Sj&ouml;gren&rsquo;s syndrome are dry eyes and dry mouth.",
"    </p>",
"    <p>",
"     This type of disease is called an autoimmune disease, meaning that the body&rsquo;s immune system attacks its own tissues or organs. Sj&ouml;gren&rsquo;s syndrome can affect one or more organ systems including the skin, lung, heart, kidney, and nerves. Some people have Sj&ouml;gren&rsquo;s syndrome as well as another autoimmune condition, such as systemic lupus erythematosus, rheumatoid arthritis, or scleroderma.",
"    </p>",
"    <p>",
"     Although there is no cure for Sj&ouml;gren&rsquo;s syndrome, a number of treatments are available. This article discusses the possible causes, signs, symptoms, diagnostic process, and treatments of Sj&ouml;gren's syndrome.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SJ&Ouml;GREN'S SYNDROME CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Sj&ouml;gren&rsquo;s syndrome is thought to be caused by the body&rsquo;s own immune system. Lymphocytes are a type of white blood cell in the body&rsquo;s immune system that normally help to protect the body from infection. In Sj&ouml;gren&rsquo;s syndrome, these cells are thought to damage the glands that produce tears and saliva.",
"    </p>",
"    <p>",
"     A person who develops Sj&ouml;gren&rsquo;s probably inherits the risk from one or both parents and is then exposed to some type of environmental trigger (eg, a viral infection), but the exact cause in not known. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25162?source=see_link\">",
"      \"Pathogenesis of Sj&ouml;gren's syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SJ&Ouml;GREN'S SYNDROME SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The classic symptoms of Sj&ouml;gren&rsquo;s syndrome are dry mouth (due to decreased production of saliva) and dry eyes (due to decreased production of tears). Symptoms of SS can develop in otherwise healthy people, especially older adults. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"      \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link\">",
"      \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SJ&Ouml;GREN'S SYNDROME DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The most prominent symptoms of Sj&ouml;gren&rsquo;s syndrome (eye and mouth dryness) are common and can be caused by conditions other than Sj&ouml;gren&rsquo;s syndrome. Therefore, it is important to identify medications or conditions that cause dryness and to determine if alternate non-drying treatments are available.",
"    </p>",
"    <p>",
"     The definition of Sj&ouml;gren&rsquo;s syndrome requires that the person have symptoms for a prolonged time (eg, dry mouth for greater than three months) and also requires positive laboratory tests. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=see_link\">",
"      \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of blood tests are typically done in people suspected of having Sj&ouml;gren&rsquo;s syndrome. One of the most important is a test for the presence of certain antibodies that are markers for autoimmune disorders. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=see_link\">",
"      \"Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Salivary gland testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;A salivary gland biopsy may be recommended to aid in the diagnosis of Sj&ouml;gren&rsquo;s syndrome. The biopsy is done by removing a small piece of tissue from the inner portion of the lip. Other salivary gland tests may also be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Eye tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tests are usually recommended to determine if you produce a normal amount of tears and to determine if there are areas of the eye that have been damaged as a result of dryness. An eye specialist (ophthalmologist) or a rheumatologist may perform these tests.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Schirmer test &mdash; In the Schirmer test, a small piece of sterile filter paper is inserted gently between the eye and eyelid in the inner corner of the eye. It is removed after several minutes, and the wetness on the paper is then measured. A decreased amount of wetting is characteristic of Sj&ouml;gren&rsquo;s syndrome, although decreased tear production can also occur with other conditions.",
"      </li>",
"      <li>",
"       Rose Bengal test &mdash; The dry eye of Sj&ouml;gren&rsquo;s syndrome can show damage to the membranes surrounding the eye and eyelids. A test called the Rose Bengal test can detect scratches on the surface of the eye.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SJ&Ouml;GREN'S SYNDROME COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The decreased fluid production in the eyes and mouth can lead to additional problems.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Damage to the surface of the eye can occur when the eyes lack the natural lubricating layer.",
"      </li>",
"      <li>",
"       Injury to the normally transparent cornea can interfere with vision and can cause eye pain.",
"      </li>",
"      <li>",
"       People with decreased saliva production are at risk of developing cavities in the teeth and infections in the mouth, including painful fungal infections (a yeast infection or thrush).",
"      </li>",
"      <li>",
"       People with Sj&ouml;gren&rsquo;s syndrome have a higher risk of developing diseases of the chest (called interstitial pneumonitis), diseases of the kidneys (interstitial nephritis), and thyroid gland abnormalities.",
"      </li>",
"      <li>",
"       Some people with Sj&ouml;gren&rsquo;s syndrome may develop inflammation of blood vessels (vasculitis). Vasculitis can cause bleeding and pain and can lead to skin, nerve,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       internal organ damage. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"        \"Patient information: Vasculitis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Sj&ouml;gren&rsquo;s also increases the risk of a cancer of the lymphatic system (such as non-Hodgkin lymphoma). The lymphatic system includes the tissues and organs that produce and store cells that fight infection, including the bone marrow, spleen, thymus, and lymph nodes. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link\">",
"        \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/60/27588?source=see_link\">",
"        \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/9/8339?source=see_link\">",
"        \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      SJ&Ouml;GREN'S SYNDROME TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of Sj&ouml;gren&rsquo;s syndrome can be divided into three basic areas (see",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link\">",
"      \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=see_link\">",
"      \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=see_link\">",
"      \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Treatment of dry eyes and mouth",
"      </li>",
"      <li>",
"       Treatment of problems such as oral yeast infections, eyelid irritation (blepharitis), and acid reflux. These problems can complicate Sj&ouml;gren&rsquo;s syndrome and can make the condition less responsive to other therapies.",
"      </li>",
"      <li>",
"       Treatment of fatigue",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       vague symptoms of poor concentration and of impaired memory (such as fibromyalgia). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"        \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Moisturizing treatments",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Dry eye treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people use artificial tears (eye drops) to treat dry eyes. Many different solutions are available; a clinician can recommend an appropriate choice based upon your pattern of dryness and of fluid production in the eye.",
"    </p>",
"    <p>",
"     Some people are sensitive to the preservatives found in artificial tears. If burning or itching occurs, a brand with a non-irritating preservative may be tried. Alternately, a preservative-free variety can be used. Eye drops without preservatives come in small, single-dose containers that may be hard for some people with joint",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     vision problems. A prescription eye drop containing cyclosporine, which suppresses part of the local immune reaction, is also available.",
"    </p>",
"    <p>",
"     At night, an eye ointment may be used to provide moisture. It is important to use only a small amount (about",
"     <span class=\"nowrap\">",
"      1/8",
"     </span>",
"     inches or 3 mm) of the ointment because overuse can block the ducts and can lead to a condition called blepharitis. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Blepharitis (eyelid inflammation)'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Preserving natural tears",
"     </span>",
"     &nbsp;&mdash;&nbsp;Various measures can be used to preserve your own tears. Shields can be fitted on the sides of glasses, helping to protect the eye from air and wind, reducing evaporation of tears. Goggles or wrap-around sunglasses serve a similar function.",
"    </p>",
"    <p>",
"     Another approach is a simple procedure called punctal occlusion. In this procedure, an ophthalmologist inserts small plugs into the tear ducts in the corner of the lower eyelid, nearest the nose, where the tears normally collect and drain into the nose. By blocking this duct, your tears stay on the eye longer. There are several types of plugs, one of which does not touch the surface of the eyeball; these plugs are generally preferred.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Stimulating saliva",
"     </span>",
"     &nbsp;&mdash;&nbsp;Simply sucking on sugarless candy or dried fruit slices (eg, peaches or nectarines) can stimulate the flow of saliva in many people. Citrus-flavored sugarless tablets and sugar-free chewing gum may also be helpful. In some people, medications (eg, pilocarpine or cevimeline) can be given to increase saliva production.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Replacing secretions in the mouth",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sipping on water throughout the day is an easy and effective treatment of dry mouth for many people. The water does not have to be swallowed. It can be rinsed around the mouth and can then be spit out.",
"    </p>",
"    <p>",
"     If this is not effective, an artificial saliva product (spray or lozenge) may be helpful. If painful gums are a problem, a gel that relieves dry mouth can be helpful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Avoiding cavities",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with Sj&ouml;gren&rsquo;s syndrome are at increased risk for dental cavities. You should brush and floss after eating meals and snacks. You should visit your dentist at least every six months for a cleaning and evaluation.",
"    </p>",
"    <p>",
"     Toothpastes designed specifically for patients with dry mouth are available. These lack the detergents that are present in many types of toothpaste, which can irritate a dry mouth. Toothbrushes with special features that help clean between the teeth (including electric toothbrushes) may also help to keep the teeth clean.",
"    </p>",
"    <p>",
"     Toothpaste with fluoride (or a special fluoride rinse or varnish) may help to prevent cavities. A fluoride treatment after each dental cleaning may also be helpful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Dryness in other areas",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with Sj&ouml;gren&rsquo;s syndrome may have dryness in other areas, including the lips, the skin, and the vagina. Dry lips may require petroleum jelly or lip salves. Dry skin usually improves with frequent and liberal use of a moisturizing cream or ointment.",
"    </p>",
"    <p>",
"     Some women with Sj&ouml;gren&rsquo;s syndrome have difficulty with vaginal dryness, especially after menopause. There are several products specifically designed for vaginal dryness, including vaginal moisturizers, estrogen cream, vitamin E oil, and vaginal lubricants; talk to your healthcare provider for specific recommendations. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"      \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Treating other problems",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Fungal infections in the mouth",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prescription medications are available to treat painful mouth lesions due to oral candidiasis (yeast infection). Sugar-free products (vaginal troches or lozenges) are often used. If you wear dentures and develop an infection, you should disinfect the dentures overnight during your treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Dry nose",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is important to treat dry nose or stuffiness because blocked nasal passages can increase mouth breathing and can worsen dry mouth. Saline nasal sprays are available in most drugstores.",
"    </p>",
"    <p>",
"     Other causes of nasal blockage, including allergy or sinus infection, should be treated promptly. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"      \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link\">",
"      \"Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Blepharitis (eyelid inflammation)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eyelid inflammation, also called blepharitis, causes symptoms that are similar to those of dry eye (swollen lids and redness of the inside of the lids). Gently washing the skin of the eyelids can relieve blepharitis. This can be done with a warm wet washcloth and with a small amount of &ldquo;no tears&rdquo; shampoo or non-soap face cleanser. With the eyes closed, the excess debris should be rubbed from the inner eye to the outer eye area. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link\">",
"      \"Blepharitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Reflux (heartburn)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acid reflux is more common in people with Sj&ouml;gren&rsquo;s syndrome. This is probably due to the decreased production of saliva, which normally helps to reduce the acidity of stomach acid. Treatment of reflux in people with Sj&ouml;gren&rsquo;s syndrome is similar to treatment in other people. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Joint and muscle pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) such as ibuprofen are recommended as treatment for the joint pains that may accompany Sj&ouml;gren&rsquo;s syndrome. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Low-dose glucocorticoids (also called steroids) such as prednisone may improve joint pain. However, glucocorticoids are generally recommended for short-term treatment because of serious side effects with long-term use (eg, weight gain, high blood pressure, diabetes, bone thinning).",
"    </p>",
"    <p>",
"     A class of medications called disease-modifying drugs (DMARDs) is commonly used in people with lupus and rheumatoid arthritis to slow the immune system&rsquo;s destructive effects. Similar treatments have been used in patients with Sj&ouml;gren&rsquo;s syndrome. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=see_link&amp;anchor=H26015964#H26015964\">",
"      \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\", section on 'Arthralgia'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Fatigue",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fatigue is common in Sj&ouml;gren&rsquo;s syndrome. Fatigue may be due to the disease itself or to difficulties staying asleep, which can occur if you drink a lot of water to treat dry mouth and then need to urinate frequently at night.",
"    </p>",
"    <p>",
"     General treatment for fatigue includes adequately controlling of dry mouth, using a humidifier in the bedroom, and practicing good sleep hygiene. Sleep hygiene uses methods that increase the chances of sleeping at night, including avoiding daytime napping, avoiding caffeine and other stimulants in the evening, observing a period of peaceful relaxation time before sleep, and ensuring that the bedroom is quiet and comfortable (",
"     <a class=\"graphic graphic_table graphicRef51203 \" href=\"mobipreview.htm?2/57/2971\">",
"      table 1",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/16/2306?source=see_link\">",
"      \"Patient information: Insomnia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Fibromyalgia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people with Sj&ouml;gren&rsquo;s syndrome also have a condition called fibromyalgia. Fibromyalgia causes muscle aching and fatigue. The treatment of fibromyalgia is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5802748\">",
"     <span class=\"h3\">",
"      Vasculitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vasculitis is inflammation of blood vessels. Damage to arteries or veins may result in bleeding, pain, and damage to skin, nerves, and internal organs. When vasculitis occurs, it often requires treatment with drugs that suppress the immune system. Medications such as cyclophosphamide, azathioprine, or mycophenolate mofetil may be prescribed by clinicians experienced in their use. Careful monitoring for side effects and for response to treatment is necessary. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"      \"Patient information: Vasculitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Anesthesia and Sj&ouml;gren's syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you need surgery for any reason, you should be certain that the anesthesiologist is aware of your diagnosis; Sj&ouml;gren&rsquo;s syndrome can increase the risks of general anesthesia. There may be an increased risk of developing mucous plugs in your airways during and after surgery, and medications used during the surgery can dry the airways further. If aware of the diagnosis of Sj&ouml;gren&rsquo;s syndrome, the anesthesiologist can take special measures to lower the risk of these complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379541\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379548\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/34/547?source=see_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/8/30850?source=see_link\">",
"      Patient information: Antinuclear antibodies (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379564\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=see_link\">",
"      Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/60/27588?source=see_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/9/8339?source=see_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link\">",
"      Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/16/2306?source=see_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379580\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=see_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/32/16906?source=see_link\">",
"      Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25162?source=see_link\">",
"      Pathogenesis of Sj&ouml;gren's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20677?source=see_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=see_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=see_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/sjogrens/sjogrens.htm\">",
"        www.ninds.nih.gov/disorders/sjogrens/sjogrens.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Sj&ouml;gren's Syndrome Foundation, Inc",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.sjogrens.org/\">",
"        www.sjogrens.org/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/conditions-treatments/disease-center/sjoumlgrens-syndrome/\">",
"        file://www.arthritis.org/conditions-treatments/disease-center/sjoumlgrens-syndrome/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       phone: 404-633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/11/44212/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/11/44212?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/1\">",
"      Ramos-Casals M, Tzioufas AG, Font J. Primary Sj&ouml;gren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/2\">",
"      Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sj&ouml;gren syndrome. Arch Intern Med 2004; 164:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/3\">",
"      Fox RI, Stern M, Michelson P. Update in Sj&ouml;gren syndrome. Curr Opin Rheumatol 2000; 12:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/4\">",
"      Soto-Rojas AE, Kraus A. The oral side of Sj&ouml;gren syndrome. Diagnosis and treatment. A review. Arch Med Res 2002; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/5\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Sis&oacute;-Almirall A, et al. Topical and systemic medications for the treatment of primary Sj&ouml;gren's syndrome. Nat Rev Rheumatol 2012; 8:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/6\">",
"      Fox RI. Sj&ouml;gren's syndrome. Lancet 2005; 366:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44212/abstract/7\">",
"      Fox RI, Liu AY. Sj&ouml;gren's syndrome in dermatology. Clin Dermatol 2006; 24:393.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f43_11_44212=[""].join("\n");
var outline_f43_11_44212=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SJ&Ouml;GREN'S SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SJ&Ouml;GREN'S SYNDROME CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SJ&Ouml;GREN'S SYNDROME SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SJ&Ouml;GREN'S SYNDROME DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SJ&Ouml;GREN'S SYNDROME COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           SJ&Ouml;GREN'S SYNDROME TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/57/2971\" title=\"table 1\">",
"           Rules for good sleep PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f43_11_44213="Endotracheal tube insertion";
var content_f43_11_44213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Insertion of the endotracheal tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 608px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insertion of the endotracheal tube. A) The tube is rotated somewhat laterally and inserted from the right of midline so that the vocal cords can be kept in view at all times. B) With the stylet in place and after molding into a hockey stick configuration, the tube is inserted into the trachea, and the laryngoscope blade is removed from the mouth. C) The stylet is removed and the tube held securely in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44213=[""].join("\n");
var outline_f43_11_44213=null;
var title_f43_11_44214="Congenital lobar emphysema";
var content_f43_11_44214=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital lobar emphysema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Christopher M Oermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/11/44214/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/11/44214/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital lobar emphysema (CLE) is a developmental anomaly of the lower respiratory tract that is characterized by hyperinflation of one or more of the pulmonary lobes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other terms for CLE include congenital lobar overinflation and infantile lobar emphysema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital lobar emphysema (CLE) is a rare congenital malformation, with a prevalence of 1 in 20,000 to 1 in 30,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/6\">",
"     6",
"    </a>",
"    ]. CLE was diagnosed in 10 of 70 patients with congenital malformations of the lung seen from 1970 to 1995 at Children's National Medical Center in Washington, DC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/7\">",
"     7",
"    </a>",
"    ]. Depending upon the pattern of referrals, other tertiary medical centers may treat one or two cases per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Males appear to be affected more than females, in a ratio of 3:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1\">",
"     1",
"    </a>",
"    ]. The reason for the male predominance is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1,3,5\">",
"     1,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive lobar hyperinflation is likely the final common pathway that results from a variety of disruptions in bronchopulmonary development. These result from abnormal interactions between embryonic endodermal and mesodermal components of the lung. Disturbances may lead to changes in the number of airways or alveoli or alveolar size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a definitive causative agent cannot be identified in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequently identified cause of congenital lobar emphysema (CLE) is obstruction of the developing airway, which occurs in 25 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1\">",
"     1",
"    </a>",
"    ]. Airway obstruction can be intrinsic or extrinsic, with the former more common. This leads to the creation of a \"ball-valve\" mechanism in which a greater volume of air enters the affected lobe during inspiration than leaves during expiration, producing air trapping.",
"   </p>",
"   <p>",
"    Intrinsic obstruction often is caused by defects in the bronchial wall, such as deficiency of bronchial cartilage. This results in airway collapse during expiration. Intraluminal obstruction caused by meconium or mucous plugs, granulomas, or mucosal folds can cause partial obstruction of a lower airway. Extrinsic compression may be caused by vascular anomalies, such as a pulmonary artery sling or anomalous pulmonary venous return, or intrathoracic masses, such as foregut cysts and teratomas. Additionally, bronchial atresia has been identified as a common finding in CLE and other congenital cystic pulmonary malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital lobar emphysema (CLE) is characterized by overdistention of one or more lobes of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/12\">",
"     12",
"    </a>",
"    ]. This leads to compression of the remaining lung tissue and herniation of the affected lobe across the anterior mediastinum into the opposite chest, causing displacement of the mediastinum.",
"   </p>",
"   <p>",
"    The different pulmonary lobes are variably affected by CLE. The left upper lobe is affected most often (40 to 50 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1,3,13,14\">",
"     1,3,13,14",
"    </a>",
"    ]. The distribution in right middle, right upper, and lower lobes is 25 to 35, 20, and 2 to 10 percent, respectively. CLE affecting multiple lobes is rare.",
"   </p>",
"   <p>",
"    Gross inspection of tissue specimens typically demonstrates hyperexpansion of the affected lobe with parenchymal pallor (",
"    <a class=\"graphic graphic_picture graphicRef70340 \" href=\"mobipreview.htm?5/16/5378\">",
"     picture 1",
"    </a>",
"    ). Histologic findings are variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/3\">",
"     3",
"    </a>",
"    ]. They range from simple, uniformly enlarged distal airways and airspaces (",
"    <a class=\"graphic graphic_picture graphicRef77991 \" href=\"mobipreview.htm?24/35/25142\">",
"     picture 2",
"    </a>",
"    ) to a polyalveolar form. In the latter, the conducting airways are normal in size and number, but the alveoli within the gas exchange units are enlarged and increased in number. True emphysematous changes are lacking in both types, leading some experts to use the term congenital lobar overinflation, rather than emphysema. Abnormal cartilage, granulation tissue, mucosal folds, or other anomalies occasionally are detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected infants usually are symptomatic in the neonatal period. Approximately 25 to 33 percent of cases present at birth, 50 percent by one month of age, and nearly all by six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive respiratory distress develops rapidly in some infants, while others have a more gradual, insidious onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1,3-5,7,8,15,16\">",
"     1,3-5,7,8,15,16",
"    </a>",
"    ], and some may remain asymptomatic for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The severity depends upon the size of the affected lobe, the compression of surrounding lung tissue, and the extent of mediastinal shift.",
"   </p>",
"   <p>",
"    Infants typically have tachypnea and increased work of breathing, and often have cyanosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1,3,4,7,8\">",
"     1,3,4,7,8",
"    </a>",
"    ]. Recurrent pneumonia or poor feeding with failure to thrive are less frequent presentations that may occur in milder forms.",
"   </p>",
"   <p>",
"    Physical examination reveals respiratory distress that often is accompanied by wheezing caused by airway compression. Breath sounds are decreased over the involved lobe, which is hyperresonant to percussion. Depending upon the extent of mediastinal shift, the cardiac point of maximal impulse may be displaced.",
"   </p>",
"   <p>",
"    Other congenital anomalies often accompany congenital lobar emphysema (CLE) and may be apparent on examination. Cardiovascular anomalies are present in 14 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1\">",
"     1",
"    </a>",
"    ]. Renal, gastrointestinal, musculoskeletal, and cutaneous disorders also may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of congenital lobar emphysema (CLE) often can be made from its characteristic appearance on a chest radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54447 \" href=\"mobipreview.htm?36/10/37039\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. The chest film typically demonstrates distension of the affected lobe and mediastinal shift, with compression and atelectasis of the contralateral lung. The diaphragm often appears flattened because of hyperinflation.",
"   </p>",
"   <p>",
"    If the chest radiograph is obtained immediately after birth, the affected lobe may appear opacified due to retained fetal lung fluid. As the fluid is absorbed and the lobe becomes filled with air, progressive hyperinflation develops.",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the chest or magnetic resonance imaging may help establish the diagnosis of CLE in atypical cases and may demonstrate an intrinsic or extrinsic source of airway obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. Studies with contrast may also demonstrate vascular causes of airway compression and resultant emphysematous changes. Alternatively, echocardiography may identify vascular structures causing airway compression.",
"   </p>",
"   <p>",
"    CT may establish a diagnosis of CLE in some infants with persistent respiratory distress and a nondiagnostic chest radiograph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/21\">",
"     21",
"    </a>",
"    ]. It also is helpful to define cystic pulmonary lesions detected by prenatal ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/10\">",
"     10",
"    </a>",
"    ]. Rarely, CT findings are nondiagnostic and definitive diagnosis is possible only on histologic evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Ventilation/perfusion",
"    </span>",
"    lung scans demonstrate decreased ventilation and perfusion in the affected lobe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1\">",
"     1",
"    </a>",
"    ]. However, they usually are not necessary for the diagnosis of CLE. Bronchoscopy also is usually not necessary for diagnosis, but may identify a source of airway obstruction.",
"   </p>",
"   <p>",
"    The radiographic appearance of congenital lobar emphysema and other developmental anomalies of the lung is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30487?source=see_link\">",
"     \"Radiographic appearance of developmental anomalies of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLE sometimes is detected by prenatal ultrasonography. Lung lesions have increased echogenicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a cystic appearance, and usually can be differentiated from other congenital lung lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. CLE lesions may decrease in size during pregnancy, similar to other lesions, such as congenital pulmonary airway malformation (CPAM; previously known as congenital cystic adenomatoid malformation, CCAM) or bronchopulmonary sequestration (BPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. A chest mass may even disappear on prenatal ultrasound and become apparent again on postnatal evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/25\">",
"     25",
"    </a>",
"    ]. Predictors of severe respiratory distress or mortality include polyhydramnios, fetal hydrops, and lung to thorax transverse area ratio",
"    <span class=\"nowrap\">",
"     (L/T",
"    </span>",
"    value) of less than 0.25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic appearance of hyperlucency of the lung can be caused by a reduction in pulmonary blood flow, or by a hyperinflation process with normal or reduced pulmonary blood flow. Thus, CLE can mimic a variety of congenital and acquired disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumothorax or localized pulmonary interstitial emphysema (PIE) &ndash; Localized PIE typically develops in infants who are mechanically ventilated at high airway pressures. Definitive diagnosis prevents potential complications related to unnecessary interventions such as tube thoracostomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/29\">",
"       29",
"      </a>",
"      ]. The emphysematous lobe in CLE usually has linear bronchovascular and alveolar markings, while these markings are absent in pneumothorax. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=see_link\">",
"       \"Pulmonary air leak in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Localized pulmonary hyperinflation &ndash; This can be caused by obstruction of the airway by a foreign body, congenital bronchial atresia, or by a mass such as a bronchogenic cyst or a pulmonary artery sling (anomalous origin of the left pulmonary artery). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Space-occupying chest lesions &ndash; Space-occupying lesions usually are easily distinguished from CLE by the radiographic findings. These include congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), and congenital diaphragmatic hernia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29144?source=see_link\">",
"       \"Bronchopulmonary sequestration\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/810?source=see_link\">",
"       \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Pulmonary growth abnormalities &ndash; Pulmonary growth abnormalities including agenesis of the pulmonary vasculature and agenesis of a lung can mimic CLE by causing hyperinflation of the contralateral lung. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30487?source=see_link&amp;anchor=H3#H3\">",
"       \"Radiographic appearance of developmental anomalies of the lung\", section on 'Agenesis'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Swyer-James-McLeod syndrome (SJM), also known as unilateral hyperlucent lung syndrome, is an uncommon disease that results in decreased pulmonary vascularity and hyperinflation that may be confined to one lung or one lobe, with or without bronchiectasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/30\">",
"       30",
"      </a>",
"      ]. SJM is now thought to be a postinfective form of bronchiolitis obliterans. Infections with adenovirus, measles, Bordetella pertussis, tuberculosis, mycoplasma pneumoniae, respiratory syncytial virus, and influenza A have been implicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. CLE and other developmental pulmonary anomalies such as unilateral pulmonary artery agenesis may mimic the findings of SJM on plain radiograph, but are distinct entities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/34\">",
"       34",
"      </a>",
"      ]. These disorders usually can be distinguished from SJM by further evaluation with CT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventilation and perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      scanning. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"      <br/>",
"      <br/>",
"      <br/>",
"      In contrast to CLE, many patients with SJM are asymptomatic and only diagnosed when chest radiographs are obtained for other indications. Airflow obstruction is generally present on pulmonary function testing, and",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      scanning often reveals a matched ventilation and perfusion defect of the affected lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. In SJM, the affected lung typically has normal to small lung size, whereas in CLE the affected lobe is expanded. Complications of SJM include recurrent infection in areas of bronchiectasis, lung abscess, and spontaneous pneumothorax [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Treatment is generally conservative, but pneumonectomy can be considered in patients with severe bronchiectasis complicated by recurrent infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/32,33,38\">",
"       32,33,38",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Poland syndrome &ndash; Poland syndrome is a constellation of congenital anomalies that include hypogenesis of the muscles of the anterior chest wall and breast tissue. This can lead to a unilateral hypolucency of the chest radiograph, which is differentiated from intrathoracic causes of hypolucency by chest CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H16#H16\">",
"       \"Diseases of the chest wall\", section on 'Poland syndrome'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109791666\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate treatment of CLE in newborns with respiratory distress is surgical resection of the affected lobe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Historically, this has meant open thoracotomy though recent advances in minimally invasive thoracoscopic surgery have resulted in decreased morbidity associated with resection of these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/43\">",
"     43",
"    </a>",
"    ]. Nevertheless, controversy remains regarding surgical excision at the time of diagnosis or conservative management in asymptomatic patients.",
"   </p>",
"   <p>",
"    Conservative management is reasonable in infants and older children who have no or minimal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/44\">",
"     44",
"    </a>",
"    ], although some infants who are asymptomatic at birth may develop progressive respiratory symptoms over time which may require surgical management. The conservative approach for infants and older children with mild symptoms is supported by a small number of case series that demonstrated clinical, and sometimes radiological, improvement in patients treated conservatively and similar long-term outcomes in mildly symptomatic patients treated surgically or conservatively, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 30 children with CLE diagnosed over a 27 year period, 21 patients underwent lobectomy whereas 9 were followed conservatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/45\">",
"       45",
"      </a>",
"      ]. The conservatively managed patients were older at the time of diagnosis. The duration of follow up ranged from 1 month to 17 years and all patients demonstrated decreased hyperexpansion of the affected lobe.",
"     </li>",
"     <li>",
"      In a report of 20 children (0 to 17 years) with CLE who were treated at a single institution between 1995 and 2002, eight were identified antenatally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/18\">",
"       18",
"      </a>",
"      ]. Among the 11 patients who were symptomatic at presentation, six were managed conservatively and showed spontaneous clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiological improvement during follow-up ranging from six months to eight years.",
"     </li>",
"     <li>",
"      In a report of 14 children (25 days to 2.5 years) with CLE who were treated at a single institution between 1991 and 1998, 10 underwent lobectomy and had an uneventful postoperative course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/15\">",
"       15",
"      </a>",
"      ]. Of those who had surgery, eight were symptomatic at birth. Four children who had milder symptoms and presented at an older age were followed conservatively. These children became asymptomatic during the follow-up period of three months to four years, although radiographic abnormalities persisted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from 1976, outcomes at an average age of 10 years were similar in six patients with CLE who were treated surgically and five who were managed conservatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/11/44214/abstract/46\">",
"     46",
"    </a>",
"    ]. Lung resection was performed in five of the six patients because of severe respiratory distress in the newborn period. One patient was asymptomatic as a newborn and had surgery at age nine years. Patients who were managed conservatively had no or minimal symptoms in the neonatal period. All patients were asymptomatic at follow-up, although two in the surgical group had occasional wheezing and labored breathing. Chest radiographs in the surgical group had generalized overinflation, while those in the conservative group had localized overinflation of the affected lobe and minimal compression of the remaining lung parenchyma. Both groups had decreased forced vital capacity, large trapped gas volume, and reduced forced expiratory flows at low lung volumes. The reductions in forced vital capacity were proportional to the unventilated volumes of lung that were either excised or chronically obstructed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8071181\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital lobar emphysema (CLE) is a developmental anomaly of the lower respiratory tract that is characterized by hyperinflation of one or more of the pulmonary lobes. Some cases are attributable to obstruction of the developing airway, which leads to air-trapping. Many infants have associated anomalies, particularly of the cardiovascular system. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Hyperinflation of one or more lobes of the lung leads to compression of the remaining lung tissue and herniation of the affected lobe across the anterior mediastinum into the opposite chest, causing displacement of the mediastinum. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 25 percent of cases present at birth, 50 percent by one month of age, and nearly all by six months of age. Infants typically have tachypnea and increased work of breathing, and often have cyanosis. Recurrent pneumonia or poor feeding with failure to thrive are less frequent presentations that may occur in milder forms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CLE often can be made from its characteristic appearance on a chest radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54447 \" href=\"mobipreview.htm?36/10/37039\">",
"       image 1",
"      </a>",
"      ). The chest film typically demonstrates distension of the affected lobe and mediastinal shift, with compression and atelectasis of the contralateral lung. Some cases are detected by prenatal ultrasonography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiographic appearance of CLE should be differentiated from pneumothorax or localized pulmonary interstitial emphysema (PIE, or pulmonary air leak), which typically develops in mechanically ventilated infants. The differential diagnosis includes other space-occupying lesions such as congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), bronchogenic cyst, congenital diaphragmatic hernia, and Swyer-James-McLeod syndrome (unilateral hyperlucent lung syndrome). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Treatment of CLE in newborns with respiratory distress consists of surgical resection of the affected lobe. Conservative management is reasonable in infants and older children who have no or minimal symptoms. Some infants who are asymptomatic at birth may also develop progressive respiratory symptoms over time which may require surgical management. (See",
"      <a class=\"local\" href=\"#H109791666\">",
"       'Treatment'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/1\">",
"      Kravitz RM. Congenital malformations of the lung. Pediatr Clin North Am 1994; 41:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/2\">",
"      Stanton M, Davenport M. Management of congenital lung lesions. Early Hum Dev 2006; 82:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/3\">",
"      Stocker JT, Drake RM, Madewell JE. Cystic and congenital lung disease in the newborn. Perspect Pediatr Pathol 1978; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/4\">",
"      Landing BH, Dixon LG. Congenital malformations and genetic disorders of the respiratory tract (larynx, trachea, bronchi, and lungs). Am Rev Respir Dis 1979; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/5\">",
"      Hernanz-Schulman M. Cysts and cystlike lesions of the lung. Radiol Clin North Am 1993; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/6\">",
"      Thakral CL, Maji DC, Sajwani MJ. Congenital lobar emphysema: experience with 21 cases. Pediatr Surg Int 2001; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/7\">",
"      Schwartz MZ, Ramachandran P. Congenital malformations of the lung and mediastinum--a quarter century of experience from a single institution. J Pediatr Surg 1997; 32:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/8\">",
"      Nuchtern JG, Harberg FJ. Congenital lung cysts. Semin Pediatr Surg 1994; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/9\">",
"      Tander B, Yal&ccedil;in M, Yilmaz B, et al. Congenital lobar emphysema: a clinicopathologic evaluation of 14 cases. Eur J Pediatr Surg 2003; 13:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/10\">",
"      Olutoye OO, Coleman BG, Hubbard AM, Adzick NS. Prenatal diagnosis and management of congenital lobar emphysema. J Pediatr Surg 2000; 35:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/11\">",
"      Riedlinger WF, Vargas SO, Jennings RW, et al. Bronchial atresia is common to extralobar sequestration, intralobar sequestration, congenital cystic adenomatoid malformation, and lobar emphysema. Pediatr Dev Pathol 2006; 9:361.",
"     </a>",
"    </li>",
"    <li>",
"     Clements BS. Congenital malformations of the lungs and airways. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI (Eds), Mosby, St. Louis 1999. p.1123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/13\">",
"      DeLuca FG, Wesselhoeft CW. Surgically treatable causes of neonatal respiratory distress. Clin Perinatol 1978; 5:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/14\">",
"      Shanti CM, Klein MD. Cystic lung disease. Semin Pediatr Surg 2008; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/15\">",
"      Karnak I, Senocak ME, Ciftci AO, B&uuml;y&uuml;kpamuk&ccedil;u N. Congenital lobar emphysema: diagnostic and therapeutic considerations. J Pediatr Surg 1999; 34:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/16\">",
"      Stigers KB, Woodring JH, Kanga JF. The clinical and imaging spectrum of findings in patients with congenital lobar emphysema. Pediatr Pulmonol 1992; 14:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/17\">",
"      Critchley PS, Forrester-Wood CP, Ridley PD. Adult congenital lobar emphysema in pregnancy. Thorax 1995; 50:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/18\">",
"      Mei-Zahav M, Konen O, Manson D, Langer JC. Is congenital lobar emphysema a surgical disease? J Pediatr Surg 2006; 41:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/19\">",
"      Markowitz RI, Mercurio MR, Vahjen GA, et al. Congenital lobar emphysema. The roles of CT and V/Q scan. Clin Pediatr (Phila) 1989; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/20\">",
"      Pardes JG, Auh YH, Blomquist K, et al. CT diagnosis of congenital lobar emphysema. J Comput Assist Tomogr 1983; 7:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/21\">",
"      Rusakow LS, Khare S. Radiographically occult congenital lobar emphysema presenting as unexplained neonatal tachypnea. Pediatr Pulmonol 2001; 32:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/22\">",
"      Ankermann T, Oppermann HC, Engler S, et al. Congenital masses of the lung, cystic adenomatoid malformation versus congenital lobar emphysema: prenatal diagnosis and implications for postnatal treatment. J Ultrasound Med 2004; 23:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/23\">",
"      Babu R, Kyle P, Spicer RD. Prenatal sonographic features of congenital lobar emphysema. Fetal Diagn Ther 2001; 16:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/24\">",
"      Liu YP, Shih SL. Congenital lobar emphysema: appearance on fetal MRI. Pediatr Radiol 2008; 38:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/25\">",
"      Quinton AE, Smoleniec JS. Congenital lobar emphysema--the disappearing chest mass: antenatal ultrasound appearance. Ultrasound Obstet Gynecol 2001; 17:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/26\">",
"      Usui N, Kamata S, Sawai T, et al. Outcome predictors for infants with cystic lung disease. J Pediatr Surg 2004; 39:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/27\">",
"      Dillman JR, Sanchez R, Ladino-Torres MF, et al. Expanding upon the unilateral hyperlucent hemithorax in children. Radiographics 2011; 31:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/28\">",
"      Wasilewska E, Lee EY, Eisenberg RL. Unilateral hyperlucent lung in children. AJR Am J Roentgenol 2012; 198:W400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/29\">",
"      Powers JE, Counselman FL. Congenital lobar emphysema: tube thoracostomy not the treatment. Pediatr Emerg Care 2005; 21:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/30\">",
"      Lucaya J, Gartner S, Garc&iacute;a-Pe&ntilde;a P, et al. Spectrum of manifestations of Swyer-James-MacLeod syndrome. J Comput Assist Tomogr 1998; 22:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/31\">",
"      Trimis G, Theodoridou M, Mostrou G, Kakavakis K. Swyer-James (MacLeod's) syndrome following pertussis infection in an infant. Scand J Infect Dis 2003; 35:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/32\">",
"      Fregonese L, Girosi D, Battistini E, et al. Clinical, physiologic, and roentgenographic changes after pneumonectomy in a boy with Macleod/Swyer-James syndrome and bronchiectasis. Pediatr Pulmonol 2002; 34:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/33\">",
"      da Silva PS, Lopes R, Neto HM. Swyer-James-MacLeod syndrome in a surgically treated child: a case report and brief literature review. J Pediatr Surg 2012; 47:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/34\">",
"      Chen IC, Chen YW, Lin SH, et al. Usefulness of combination of pulmonary ventilation and perfusion scintigraphy on the diagnosis of children with unilateral hyperlucent lung. Nucl Med Commun 2011; 32:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/35\">",
"      Arslan N, Ilgan S, Ozkan M, et al. Utility of ventilation and perfusion scan in the diagnosis of young military recruits with an incidental finding of hyperlucent lung. Nucl Med Commun 2001; 22:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/36\">",
"      Wang JY, Chen KY, Chang YC, et al. Swyer-James syndrome complicated by lung abscess. J Formos Med Assoc 2000; 99:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/37\">",
"      Soni R, Barnes D. Macleod's syndrome presenting with spontaneous pneumothorax. Respirology 1999; 4:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/38\">",
"      Koyama T, Osada H, Kitanaka Y, et al. Surgically treated Swyer-James syndrome. Jpn J Thorac Cardiovasc Surg 2001; 49:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/39\">",
"      Duan M, Wang L, Cao Y, et al. Results of surgical treatment of congenital cystic lung disease. Thorac Cardiovasc Surg 2005; 53:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/40\">",
"      Shanmugam G, MacArthur K, Pollock JC. Congenital lung malformations--antenatal and postnatal evaluation and management. Eur J Cardiothorac Surg 2005; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/41\">",
"      Ayed AK, Owayed A. Pulmonary resection in infants for congenital pulmonary malformation. Chest 2003; 124:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/42\">",
"      Choudhury SR, Chadha R, Mishra A, et al. Lung resections in children for congenital and acquired lesions. Pediatr Surg Int 2007; 23:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/43\">",
"      Truitt AK, Carr SR, Cassese J, et al. Perinatal management of congenital cystic lung lesions in the age of minimally invasive surgery. J Pediatr Surg 2006; 41:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/44\">",
"      Eber E. Antenatal diagnosis of congenital thoracic malformations: early surgery, late surgery, or no surgery? Semin Respir Crit Care Med 2007; 28:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/45\">",
"      Oz&ccedil;elik U, G&ouml;&ccedil;men A, Kiper N, et al. Congenital lobar emphysema: evaluation and long-term follow-up of thirty cases at a single center. Pediatr Pulmonol 2003; 35:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/11/44214/abstract/46\">",
"      Eigen H, Lemen RJ, Waring WW. Congenital lobar emphysema: long-term evaluation of surgically and conservatively treated children. Am Rev Respir Dis 1976; 113:823.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6350 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44214=[""].join("\n");
var outline_f43_11_44214=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8071181\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109791666\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8071181\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6350|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/10/37039\" title=\"diagnostic image 1\">",
"      Congenital lobar emphysema chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6350|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/16/5378\" title=\"picture 1\">",
"      Congenital lobar emphysema gross pathologic specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/35/25142\" title=\"picture 2\">",
"      Congenital lobar emphysema histology section",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29144?source=related_link\">",
"      Bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=related_link\">",
"      Pulmonary air leak in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30487?source=related_link\">",
"      Radiographic appearance of developmental anomalies of the lung",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_11_44215="Schiller-Duval body";
var content_f43_11_44215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    A Schiller-Duval body in yolk sac tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Crum CP. The Female Genital Tract. In: Pathologic Basis of Disease, 6th ed, Cotran RS, Kumar V, Collins T (Eds), WB Saunders Company, Pennsylvania 1999. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44215=[""].join("\n");
var outline_f43_11_44215=null;
var title_f43_11_44216="Ciprofloxacin (systemic): Pediatric drug information";
var content_f43_11_44216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=see_link\">",
"    see \"Ciprofloxacin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=see_link\">",
"    see \"Ciprofloxacin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9611220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg;;",
"     </li>",
"     <li>",
"      Cipro&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9611234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ciproflox&reg;;",
"     </li>",
"     <li>",
"      Auro-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Ciprofloxacin Injection;",
"     </li>",
"     <li>",
"      Ciprofloxacin Intravenous Infusion;",
"     </li>",
"     <li>",
"      Cipro&reg;;",
"     </li>",
"     <li>",
"      Cipro&reg; XL;",
"     </li>",
"     <li>",
"      CO Ciprofloxacin;",
"     </li>",
"     <li>",
"      Dom-Ciprofloxacin;",
"     </li>",
"     <li>",
"      JAMP-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mar-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mint-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mylan-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Novo-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PHL-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PMS-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PRO-Ciprofloxacin;",
"     </li>",
"     <li>",
"      RAN&trade;-Ciproflox;",
"     </li>",
"     <li>",
"      ratio-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Riva-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Sandoz-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Taro-Ciprofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10586604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Limited data available: 10 mg/kg/dose every 12 hours (Kaguelidou, 2011). A study of 20 neonates (28-36 weeks) showed this dose produced serum concentrations sufficient to treat common gram-negative pathogens. A higher daily dose divided into shorter intervals may be required to achieve serum concentrations sufficient to treat",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     or",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     (Aggarwal, 2004). Reported range: 10-60 mg/kg/day (Krcm&eacute;ry, 1999; Schaad, 1995; van den Oever, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10586944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=see_link\">",
"      see \"Ciprofloxacin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Extended release tablets and immediate release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate release formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 20-30 mg/kg/day in 2 divided doses; maximum dose: 1.5 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 20-30 mg/kg/day divided every 12 hours; maximum dose: 800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalational anthrax (postexposure): Initial treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 20 mg/kg/day divided every 12 hours for 60 days; maximum dose: 800 mg/day (substitute oral antibiotics for I.V. antibiotics as soon as clinical condition improves)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 30 mg/kg/day divided every 12 hours for 60 days; maximum dose: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Complicated UTI or pyelonephritis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 18-30 mg/kg/day divided every 8 hours for 10-21 days; maximum dose: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 20-40 mg/kg/day divided every 12 hours for 10-21 days; maximum dose: 1500 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cystic fibrosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 40 mg/kg/day divided every 12 hours; maximum dose: 2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 30 mg/kg/day divided every 8-12 hours; maximum dose: 1.2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 250-750 mg every 12 hours, depending on severity of infection and susceptibility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Acute sinusitis: Mild/moderate: 500 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Uncomplicated UTI/acute cystitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Extended release tablet: 500 mg every 24 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release formulation: Acute uncomplicated: 250 mg every 12 hours for 3 days; 250 mg every 12 hours for 7-14 days for mild to moderate UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Complicated UTI or acute uncomplicated pyelonephritis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Extended release tablet: 1000 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release formulation: 500 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bone and joint infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild/moderate: 500 mg every 12 hours for &ge;4 to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe/complicated: 750 mg every 12 hours for &ge;4 to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chemoprophylaxis regimen for high-risk contacts of invasive meningococcal disease: 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chronic bacterial prostatitis: 500 mg every 12 hours for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infectious diarrhea: 500 mg every 12 hours for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Skin and skin structure infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild/moderate: 500 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe/complicated: 750 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Uncomplicated gonorrhea: 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chancroid: 500 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lower respiratory tract infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild/moderate: 500 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe/complicated: 750 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Typhoid fever: 500 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Inhalational anthrax (postexposure prophylaxis): 500 mg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 200-400 mg every 8-12 hours depending on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lower respiratory tract, skin and skin structure infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild/moderate: 400 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe/complicated: 400 mg every 8 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment of anthrax infection: 400 mg every 12 hours for 60 days (substitute oral antibiotics for I.V. antibiotics as soon as clinical condition improves)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Empiric therapy in febrile neutropenic patients: 400 mg every 8 hours in combination with piperacillin for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Dosage adjustments are not provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007): I.V., Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &ge;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR 10-29 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : 10-15 mg/kg/dose every 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &lt;10 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : 10-15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis/peritoneal dialysis (PD) (after dialysis on dialysis days): 10-15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CRRT: 10-15 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral, immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Oral: 250-500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-29 mL/minute: 250-500 mg every 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Hemodialysis/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 250-500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-29 mL/minute: 200-400 mg every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate recommendations: Oral (immediate release), I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% to 75% of usual dose every 12 hours (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of usual dose every 12 hours (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Minimally dialyzable (&lt;10%): Oral: 250-500 mg every 24 hours or I.V.: 200-400 mg every 24 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     CVVH/CVVHD/CVVHDF: I.V.: 200-400 mg every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9611523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg; I.V.: 200 mg (100 mL [DSC]); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [preservative free]: 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (20 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microcapsules for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg;: 250 mg/5 mL (100 mL) [contains sucrose 1.4 g/5 mL; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg;: 500 mg/5 mL (100 mL) [contains sucrose 1.3 g/5 mL; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride [strength expressed as base]: 100 mg, 250 mg, 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as base and hydrochloride [strength expressed as base]: 500 mg, 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9611236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes suspension",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9611231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cipro&reg;:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s701984744198575120780282147325L.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s701984744198575120780282147325L.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10586949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May administer with food to minimize GI upset; avoid antacid use; maintain proper hydration and urine output. Administer immediate release ciprofloxacin and Cipro&reg; XR at least 2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc (including dairy products or calcium-fortified juices). Separate oral administration from drugs which may impair absorption (see Drug Interactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Patients should avoid chewing on the microcapsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasogastric/orogastric tube: Crush immediate release tablet and mix with water. Flush feeding tube before and after administration. Hold tube feedings at least 1 hour before and 2 hours after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release: Do not crush, split, or chew. May be administered with meals containing dairy products (calcium content &lt;800 mg), but not with dairy products alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer by slow I.V. infusion over 60 minutes to reduce the risk of venous irritation (burning, pain, erythema, and swelling); final concentration for administration should not exceed 2 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9611369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS, SWFI;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amiodarone, anidulafungin, aztreonam, bivalirudin, calcium gluconate, ceftazidime, cisatracurium, cyclosporine, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, etoposide phosphate, fenoldopam, gallium nitrate, gemcitabine, gentamicin, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydroxyzine, lidocaine, linezolid, lorazepam, metoclopramide, metronidazole, midazolam, milrinone, piperacillin, potassium acetate, potassium chloride, promethazine, quinupristin and dalfopristin, ranitidine, remifentanil, tacrolimus, telavancin, teniposide, thiotepa, tigecycline, tobramycin, vasopressin, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, ampicillin/sulbactam, azithromycin, cefepime, dexamethasone sodium phosphate, drotrecogin alfa, furosemide, hydrocortisone sodium succinate, methylprednisolone sodium succinate, pantoprazole, pemetrexed, phenytoin, potassium phosphate, propofol, vancomycin, warfarin. Variable (consult detailed reference): Caspofungin, heparin, magnesium sulfate, sodium bicarbonate, sodium phosphates.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10586744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Premixed bags: Out of overwrap stability: 14 days at room temperature; reconstituted oral suspension: Stable for 14 days when stored at room temperature or refrigerated; store tablets, intact injection vial, and oral suspension prior to reconstitution at room temperature; protect from intense light; protect from freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10586605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of documented or suspected pseudomonal infection of the respiratory or urinary tract, skin and soft tissue, and bone and joint; treatment of complicated UTIs and pyelonephritis in children 1-17 years of age due to",
"     <i>",
"      E. coli",
"     </i>",
"     ; documented multidrug-resistant, aerobic gram-negative bacilli, some gram-positive staphylococci, and",
"     <i>",
"      Mycobacterium tuberculosis",
"     </i>",
"     ; documented infectious diarrhea due to",
"     <i>",
"      Campylobacter jejuni",
"     </i>",
"     ,",
"     <i>",
"      Shigella",
"     </i>",
"     , or",
"     <i>",
"      E. coli",
"     </i>",
"     ; typhoid fever caused by",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     ; osteomyelitis caused by susceptible organisms in which parenteral therapy is not feasible; uncomplicated cervical and urethral gonorrhea due to",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ; chronic bacterial prostatitis caused by",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Proteus mirabilis",
"     </i>",
"     ; pulmonary exacerbation of cystic fibrosis; empiric therapy for febrile neutropenia in combination with piperacillin; initial therapy or postexposure prophylaxis for inhalational anthrax; extended release tablet is used for the treatment of UTI and acute uncomplicated pyelonephritis caused by susceptible",
"     <i>",
"      E. coli",
"     </i>",
"     and",
"     <i>",
"      Klebsiella pneumoniae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3198418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciprofloxacin may be confused with cephalexin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cipro&reg; may be confused with Ceftin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9611306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, headache (I.V. administration); neurologic events (includes dizziness, insomnia, nervousness, somnolence); restlessness (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal gait, acute generalized exanthemous pustulosis (AGEP), acute renal failure, agitation, agranulocytosis, albuminuria, alkaline phosphatase increase, allergic reactions, anaphylactic shock, anemia, angina pectoris, angioedema, anorexia,anxiety, arthralgia, ataxia, atrial flutter, bilirubin (serum) increase, bone marrow depression (life-threatening), bronchospasm, BUN increased, candidiasis, cardiopulmonary arrest, chills, cholestatic jaundice, chromatopsia,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), confusion, constipation, CPK increase, crystalluria (particularly in alkaline urine), cylindruria, delirium, depression (including self-injurious behavior), dizziness, drowsiness, dyspepsia (adults), dyspnea, edema, eosinophilia, erythema multiforme/nodosum, exfoliative dermatitis, fever (adults), fixed eruption, gastrointestinal bleeding, gout flare, hallucinations, headache (oral), hematocrit decreased, hematuria, hemoglobin decreased, hemolytic anemia, hepatic failure (some fatal), hepatic necrosis, hyper-/hypoglycemia, hyper-/hypotension, hyperesthesia, hyperpigmentation, hypertonia, insomnia, interstitial nephritis, intestinal perforation, intracranial pressure increased, irritability, joint pain, laryngeal edema, LDH increased, lightheadedness, lipase increased, lymphadenopathy, malaise, manic reaction, methemoglobinemia, MI, migraine, myalgia, myasthenia gravis exacerbation, myoclonus, nephritis, nightmares, nystagmus, palpitation, pancreatitis, pancytopenia (life-threatening or fatal), paranoia, peripheral neuropathy, petechiae, photosensitivity/toxicity, pneumonitis, polyneuropathy, prolongation of PT/INR (in patients treated with vitamin K antagonists), pseudotumor cerebri, psychosis (toxic), PT decrease, pulmonary edema, renal calculi, seizure (including grand mal), serum cholesterol increased, serum creatinine increased, serum sickness-like reactions, serum triglycerides increased, status epilepticus, Stevens-Johnson syndrome, suicidal thoughts/ideation/attempts and completions, syncope, tachycardia, taste loss, tendon rupture, tendonitis, thrombocytopenia, thrombocytosis, thrombophlebitis, tinnitus, torsade de pointes, toxic epidermal necrolysis, tremor, twitching, unresponsiveness, urethral bleeding, uric acid increased, vaginitis, vasculitis, ventricular arrhythmia, visual disturbance, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10586624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, any component, or other quinolones; concomitant administration with tizanidine; not recommended for use in pregnant women or during breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10586684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with known or suspected CNS disorders, seizure disorders, severe cerebral arteriosclerosis, or renal impairment; modify dosage in patients with renal impairment. Avoid excessive sunlight and take precautions to limit exposure (eg, loose-fitting clothing, sunscreen); may rarely cause moderate-to-severe phototoxicity reactions. Discontinue use if phototoxicity occurs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10586625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ciprofloxacin is not a drug of first choice in the pediatric population due to reported adverse events related to joints and/or surrounding tissues. Ciprofloxacin has caused arthropathy with erosions of the cartilage in weight-bearing joints of immature animals; green discoloration of teeth in newborns has been reported; Achilles tendonitis and tendon rupture have been reported with fluoroquinolones in patients of all ages",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk increased in patients taking concomitant corticosteroids, patients &gt;60 years of age, and in patients with kidney, heart, or lung transplants. Prolonged use may result in superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis; CNS stimulation, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis may occur, resulting in tremors, restlessness, confusion, and very rarely hallucinations, depression, nightmares, suicidal ideation, or convulsive seizures. If these reactions occur, discontinue ciprofloxacin. Rare cases of polyneuropathy affecting small and/or large axons, resulting in paresthesias, hypoesthesias, dysesthesias, and weakness, have been reported in patients receiving ciprofloxacin. Discontinue ciprofloxacin if patient experiences pain, burning, tingling, numbness, or weakness or is found to have deficits in light touch, pain, temperature, position sense, vibrating sensation, or motor strength. Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness associated with myasthenia gravis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; cases of severe exacerbations, including the need for ventilatory support and deaths, have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Coadministration of ciprofloxacin with drugs metabolized by CYP1A2 (eg, theophylline, caffeine, tizanidine) may result in increased plasma concentrations of the coadministered drug with corresponding side effects. Serious and fatal reactions, including cardiac arrest, seizure, status epilepticus, and respiratory failure, have been reported in patients receiving ciprofloxacin and theophylline concurrently. Serum theophylline levels should be monitored and dosage adjustments made when concomitant use cannot be avoided. Hypotension and oversedation have been reported when ciprofloxacin and tizanidine were given concomitantly (concomitant administration of tizanidine and ciprofloxacin is contraindicated). Severe hypersensitivity reactions, including life-threatening anaphylactic shock, have been reported in patients receiving quinolones. If an allergic reaction occurs, discontinue drug immediately.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9611328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: Quinolone Antibiotics may decrease the metabolism of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Ciprofloxacin (Systemic) may increase the serum concentration of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Ciprofloxacin (Systemic) may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: Ciprofloxacin (Systemic) may enhance the adverse/toxic effect of Pentoxifylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: Ciprofloxacin (Systemic) may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Ciprofloxacin (Systemic) may decrease the metabolism of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ropivacaine: Ciprofloxacin (Systemic) may decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Quinolone Antibiotics may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Ciprofloxacin (Systemic) may decrease the metabolism of TiZANidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10586686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dairy foods (milk, yogurt) and mineral supplements decrease ciprofloxacin concentrations; avoid concomitant administration with dairy products, enteral feedings (enteral feeds need to be discontinued for 1-2 hours prior to and after ciprofloxacin administration), mineral supplements, iron, zinc, or calcium-fortified juices; ciprofloxacin increases caffeine concentrations; use caution with xanthine-containing foods and beverages",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9611259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9611260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid and cord serum (Ludlam, 1997). An increased risk of teratogenic effects has not been observed in animals or humans following ciprofloxacin use during pregnancy; however, because of concerns of cartilage damage in immature animals, ciprofloxacin should only be used during pregnancy if a safer option is not available. Ciprofloxacin is recommended for prophylaxis and treatment of pregnant women exposed to anthrax (CDC, 2001a; CDC, 2001b). Serum concentrations of ciprofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou, 1989).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10587004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal, hepatic, and hematopoietic function periodically; monitor number and type of stools/day for diarrhea. Patients receiving concurrent ciprofloxacin and theophylline should have serum levels of theophylline monitored; monitor INR in patients receiving warfarin; patients receiving concurrent ciprofloxacin and cyclosporine should have cyclosporine levels monitored.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10587005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid peak serum concentrations &gt;5 mcg/mL.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10586768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-gyrase and topoisomerase I.V. in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10586769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Well-absorbed; 500 mg orally every 12 hours produces an equivalent AUC to that produced by 400 mg I.V. over 60 minutes every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed into body tissues and fluids with high concentration in bile, saliva, urine, sputum, stool, lungs, liver, skin, muscle, prostate, genital tissue, and bone; low concentration in CSF; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 16% to 43%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Partially in the liver to four active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: 50% to 85%; younger CF patients have a lower bioavailability of 68% vs CF patients &gt;13 years of age with bioavailability of 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults with normal renal function: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Oral: Immediate release tablet: Within 0.5-2 hours; Extended release tablet: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 30% to 50% excreted as unchanged drug in urine via glomerular filtration and active tubular secretion; 20% to 40% excreted in feces primarily from biliary excretion; &lt;1% excreted in bile as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: After I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CF child: 0.84 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adult: 0.5-0.6 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Only small amounts of ciprofloxacin are removed by dialysis (&lt;10%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10587045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=see_link\">",
"      see \"Ciprofloxacin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not chew microcapsules of the oral suspension; do not split, crush, or chew extended release tablet; avoid caffeine; may cause dizziness or lightheadedness and impair ability to perform activities requiring mental alertness or physical coordination. Notify physician of tendon pain or swelling; signs of allergy; burning, tingling, numbness, or weakness; or persistent diarrhea. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10587050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although fluoroquinolones are only FDA approved for use in children for complicated UTI, pyelonephritis, and postexposure treatment for inhalational anthrax, the AAP has provided a list of other possible uses for fluoroquinolones once risks and benefits have been assessed to justify its use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; UTI caused by",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     or other multidrug-resistant, gram-negative bacteria susceptible to fluoroquinolones",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Chronic suppurative otitis media or otitis externa caused by",
"     <i>",
"      P. aeruginosa",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Chronic or acute osteomyelitis or osteochondritis caused by",
"     <i>",
"      P. aeruginosa",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Mycobacterial infections caused by isolates sensitive to fluoroquinolones",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Gram-negative bacterial infections in immunocompromised hosts in which oral therapy is desired or resistance to alternative agents is present",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 50 mg/mL oral suspension may be made using 2 different vehicles (a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Methylcellulose 1% and Simple Syrup, NF). Crush twenty 500 mg tablets and reduce to a fine powder. Add a small amount of vehicle and mix to a uniform paste; mix while adding the vehicle in geometric proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label \"shake well\" and \"refrigerate\". Stable 91 days refrigerated and 70 days at room temperature.",
"     <b>",
"      Note:",
"     </b>",
"     Microcapsules for oral suspension available (50 mg/mL; 100 mg/mL); not for use in feeding tubes.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aggarwal P, Dutta S, Garg SK, et al, \"Multiple Dose Pharmacokinetics of Ciprofloxacin in Preterm Babies,\"",
"      <i>",
"       Indian Pediatr",
"      </i>",
"      , 2004, 41(10):1001-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/15523125/pubmed\" id=\"15523125\" target=\"_blank\">",
"        15523125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 66, 171.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campoli-Richards DM, Monk JP, Price A, et al, \"Ciprofloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 1988, 35(4):373-447.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/3292209/pubmed\" id=\"3292209\" target=\"_blank\">",
"        3292209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inglesby TV, Henderson DA, Bartlett JG, et al, \"Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1999, 281(18):1735-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/10328075/pubmed\" id=\"10328075\" target=\"_blank\">",
"        10328075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaguelidou F, Turner MA, Choonara I, et al, \"Ciprofloxacin Use in Neonates: A Systematic Review of the Literature,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2011, 30(2):e29-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/21048525/pubmed\" id=\"21048525\" target=\"_blank\">",
"        21048525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krcm&eacute;ry V Jr, Filka J, Uher J, et al, \"Ciprofloxacin in Treatment of Nosocomial Meningitis in Neonates and in Infants: Report of 12 Cases and Review,\"",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 1999, 35(1):75-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/10529884/pubmed\" id=\"10529884\" target=\"_blank\">",
"        10529884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez WJ and Wiedermann BL, \"The Role of Newer Oral Cephalosporins, Fluoroquinolones, and Macrolides in the Treatment of Pediatric Infections,\"",
"      <i>",
"       Adv Pediatr Infect Dis",
"      </i>",
"      , 1994, 9:125-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/8123221/pubmed\" id=\"8123221\" target=\"_blank\">",
"        8123221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubio TT, Miles MV, Lettieri JT, et al, \"Pharmacokinetic Disposition of Sequential Intravenous/Oral Ciprofloxacin in Pediatric Cystic Fibrosis Patients With Acute Pulmonary Exacerbation,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1997, 16(1):112-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/9002120/pubmed\" id=\"9002120\" target=\"_blank\">",
"        9002120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaad UB, abdus Salam M, Aujard Y, et al, \"Use of Fluoroquinolones in Pediatrics: Consensus Report of an International Society of Chemotherapy Commission,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(1):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/7715981/pubmed\" id=\"7715981\" target=\"_blank\">",
"        7715981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Oever HL, Versteegh FG, Thewessen EA, et al, \"Ciprofloxacin in Preterm Neonates: Case Report and Review of the Literature,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1998, 157(10):843-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44216/abstract-text/9809826/pubmed\" id=\"9809826\" target=\"_blank\">",
"        9809826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15951 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44216=[""].join("\n");
var outline_f43_11_44216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611220\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611233\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611234\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586604\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442266\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586944\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611236\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611231\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586949\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611369\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586744\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586605\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198418\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611306\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586624\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586684\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586625\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611328\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586686\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611259\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611260\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587004\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587005\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586768\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586769\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587045\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587050\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806353\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_11_44217="Fosamprenavir: Drug information";
var content_f43_11_44217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosamprenavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/5/32853?source=see_link\">",
"    see \"Fosamprenavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/28/36297?source=see_link\">",
"    see \"Fosamprenavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Telzir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiretroviral therapy-naive patients:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unboosted regimen (per manufacturer&rsquo;s labeling):",
"     </i>",
"     1400 mg twice daily (without ritonavir);",
"     <b>",
"      Note:",
"     </b>",
"     This regimen is not recommended in adults due to inferior potency compared to other protease inhibitor based regimens and the potential for cross-resistance to darunavir (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ritonavir-boosted regimens:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-daily regimen: Fosamprenavir 1400 mg plus ritonavir 100-200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twice-daily regimen: Fosamprenavir 700 mg plus ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Protease inhibitor (PI)-experienced patients:",
"     </b>",
"     Fosamprenavir 700 mg plus ritonavir 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Once-daily administration is not recommended in protease inhibitor-experienced patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustments for concomitant therapy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Combination therapy with efavirenz (ritonavir-boosted regimen):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Once-daily regimen (PI-naive patients only): Fosamprenavir 1400 mg plus ritonavir 300 mg plus efavirenz 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Twice-daily regimen: Fosamprenavir 700 mg plus ritonavir 100 mg twice daily plus efavirenz 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Combination therapy with maraviroc:",
"     </b>",
"     Fosamprenavir 700 mg plus ritonavir 100 mg plus maraviroc 150 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5062602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/28/36297?source=see_link\">",
"      see \"Fosamprenavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     Infants &ge;4 weeks to Children &lt;18 years:",
"     <b>",
"      Note:",
"     </b>",
"     Twice-daily dosing is recommended; once-daily dosing (without or without ritonavir) is",
"     <b>",
"      not",
"     </b>",
"     recommended in any pediatric patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Protease inhibitor (PI)-naive patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Ritonavir-boosted regimen:",
"     </i>",
"     Infants &ge;4 weeks:",
"     <b>",
"      Note:",
"     </b>",
"     Should not be administered to infants born &lt; 38 weeks gestation and who have not attained a postnatal age of 28 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;11 kg: Fosamprenavir 45 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 7 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     11 to &lt;15 kg: Fosamprenavir 30 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15  to &lt;20 kg: Fosamprenavir 23 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;20 kg: Fosamprenavir 18 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When combined with ritonavir, the adult regimen of fosamprenavir 700 mg plus ritonavir 100 mg twice daily can be used in children who weigh &ge;39 kg while ritonavir capsules may be used for children who weigh &ge;33 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Unboosted regimen:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;2 years: Fosamprenavir without ritonavir is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;2 years and &lt;47 kg: Fosamprenavir 30 mg/kg/dose twice daily (not to exceed adult dosage of 1400 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;2 years and &ge;47 kg: The adult regimen of fosamprenavir 1400 mg twice daily may be used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Protease inhibitor (PI)-experienced patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Ritonavir-boosted regimen:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants &lt;6 months: Not recommended in PI-experienced patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants &ge;6 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &lt;11 kg: Fosamprenavir 45 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 7 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     11 to &lt;15 kg: Fosamprenavir 30 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     15  to &lt;20 kg: Fosamprenavir 23 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;20 kg: Fosamprenavir 18 mg/kg/dose twice daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily (maximum: fosamprenavir 700 mg/ritonavir 100 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When combined with ritonavir, the adult regimen of fosamprenavir 700 mg plus ritonavir 100 mg twice daily can be used in children who weigh &ge;39 kg while ritonavir capsules may be used for children who weigh &ge;33 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Unboosted regimen:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     No information provided in manufacturer&rsquo;s labeling regarding unboosted fosamprenavir in PI-experienced pediatric patients except that fosamprenavir without ritonavir is not recommended in children &lt;2 years of age and the adult unboosted regimen of 1400 mg twice daily may be used for pediatric patients who weigh &ge;47 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use of fosamprenavir without ritonavir (unboosted regimen) is not an approved use in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      PI-naive  and PI-experienced patients:",
"     </b>",
"     <i>",
"      Ritonavir boosted regimen:",
"     </i>",
"     Children &ge;6 years: 18 mg/kg/dose",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 3 mg/kg/dose twice daily; maximum dose: fosamprenavir 700 mg/ritonavir 100 mg twice daily; adult regimen of fosamprenavir 700 mg/ritonavir 100 mg twice daily can be used in children who weigh &ge;39 kg while ritonavir tablets may be used for children who weigh &ge;33 kg and can swallow tablets whole.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adults (not established in pediatric patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh score 5-6): Reduce dosage of fosamprenavir to 700 mg twice daily without concurrent ritonavir (therapy naive)",
"     <b>",
"      or",
"     </b>",
"     fosamprenavir 700 mg twice daily plus ritonavir 100 mg once daily (therapy naive or PI experienced).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment (Child-Pugh score 7-9): Reduce dosage of fosamprenavir to 700 mg twice daily without concurrent ritonavir (therapy naive)",
"     <b>",
"      or",
"     </b>",
"     fosamprenavir 450 mg twice daily plus ritonavir 100 mg once daily (therapy naive or PI experienced).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh score 10-15): Reduce dosage of fosamprenavir to 350 mg twice daily without concurrent ritonavir (therapy naive)",
"     <b>",
"      or",
"     </b>",
"     fosamprenavir 300 mg twice daily plus ritonavir 100 mg once daily (therapy na&iuml;ve or PI experienced).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexiva&reg;: 50 mg/mL (225 mL) [contains propylene glycol; grape-bubblegum-peppermint flavor; equivalent to amprenavir ~43 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexiva&reg;: 700 mg [equivalent to amprenavir ~600 mg]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5944477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Telzir&reg;: 700 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, oral, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Telzir&reg;: 50 mg/mL (225 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5075151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Administer",
"     <b>",
"      without",
"     </b>",
"     food to adults; administer",
"     <b>",
"      with",
"     </b>",
"     food to pediatric patients. Readminister dose of suspension if emesis occurs within 30 minutes after dosing.  Shake suspension vigorously prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Administer with food if taken with ritonavir. May be administered without regard to food if not taken with ritonavir.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infections in combination with at least two other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lexiva&reg; may be confused with Levitra&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&le;19%; onset: ~11 days; duration: ~13 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (&gt;750 mg/dL: &le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (moderate-to-severe; 5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (moderate-to-severe; 2% to 4%), fatigue (moderate-to-severe; 2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (7% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (&gt;251 mg/dL: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Serum lipase increased (&gt;2 times ULN: 5% to 8%), nausea (moderate-to-severe; 3% to 7%), vomiting (moderate-to-severe; 2% to 6%), abdominal pain (moderate-to-severe; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (&lt;750 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&gt;5 times ULN: 4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, hypercholesterolemia, myocardial infarction, nephrolithiasis, oral paresthesia, QT prolongation (with amprenavir), Stevens-Johnson syndrome, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Diabetes mellitus, fat redistribution, and immune reconstitution syndrome have been associated with protease inhibitor therapy. Spontaneous bleeding has been reported in patients with hemophilia A or B following treatment with protease inhibitors. Acute hemolytic anemia has been reported in association with amprenavir use.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinically-significant hypersensitivity (eg, Stevens-Johnson syndrome) to fosamprenavir, amprenavir, or any component of the formulation; concurrent therapy with CYP3A4 substrates with a narrow therapeutic window; concomitant use with alfuzosin, cisapride, delavirdine, ergot derivatives, lovastatin, midazolam, pimozide, rifampin, simvastatin, St John's wort, and triazolam; use of flecainide and propafenone with concomitant ritonavir therapy; sildenafil (when used for pulmonary artery hypertension [eg, Revatio&reg;])",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Acute hemolytic anemia has been reported in association with amprenavir use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May cause transaminase elevations, hepatitis, and/or exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying hepatic disease, such as hepatitis B or C or cirrhosis. Dosage adjustment required in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Protease inhibitors have been associated with a variety of hypersensitivity events (some severe), including rash, anaphylaxis (rare), angioedema, bronchospasm, erythema multiforme, and/or Stevens-Johnson syndrome (rare). It is generally recommended to discontinue treatment if severe rash or moderate symptoms accompanied by other systemic symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid elevations: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrolithiasis: Cases have been reported in postmarketing surveillance; temporary or permanent discontinuation of therapy should be considered if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Use with caution in patients with sulfonamide allergy. In clinical trials, the incidence of rash did not differ appreciably in patients with or without past history of sulfonamide allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of fosamprenavir with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hormonal contraceptives: Do not use with hormonal contraceptives (eg, ethinyl estradiol/norethindrone); estrogen/progestin levels may be reduced with concomitant use. Use in combination with ritonavir may increase the risk of transaminase elevations; nonhormonal contraception is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Do not administer fosamprenavir (with or without ritonavir) to protease inhibitor-experienced pediatric patients  &lt;6 months of age. In addition, once-daily dosing of fosamprenavir (with or without ritonavir) is not recommended in any pediatric patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Protease inhibitor-experienced adults: Once-daily fosamprenavir/ritonavir is not recommended in protease inhibitor-experienced adults.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking fosamprenavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting fosamprenavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Fosamprenavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Fosamprenavir may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Fosamprenavir. Specifically, delavirdine may increase concentrations of the active metabolite amprenavir. Fosamprenavir may decrease the serum concentration of Delavirdine. The active metabolite amprenavir is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Fosamprenavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Management: For once-daily fosamprenavir/ritonavir with efavirenz, an increased ritonavir dose to 300 mg/day is recommended.  No ritonavir dose adjustment is required if using twice-daily fosamprenavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may increase.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Fosamprenavir may increase the serum concentration of Flecainide.  Management: Concurrent use of ritonavir-boosted fosamprenavir with flecainide is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with flecainide is not specifically contraindicated but should only be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Fosamprenavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fosamprenavir may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day itraconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day ketoconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Fosamprenavir may decrease the serum concentration of Lopinavir. Specifically, amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir.  Management: Lopinavir/ritonavir should not be used as a once daily regimen when used together with fosamprenavir.  The use of ritonavir-boosted fosamprenavir with lopinavir/ritonavir may negate this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Management: Coadministration of nevirapine and fosamprenavir is not recommended without concurrent ritonavir.  However, when nevirapine and fosamprenavir/ritonavir (twice daily) are used in combination, no dose adjustment is required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Fosamprenavir may decrease the serum concentration of PARoxetine. The active metabolite amprenavir is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fosamprenavir may decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically, phenytoin may increase the concentration of the active metabolite amprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Fosamprenavir may increase the serum concentration of Propafenone.  Management: Concurrent use of ritonavir-boosted fosamprenavir with propafenone is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with propafenone is not specifically contraindicated but should only be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Fosamprenavir may decrease the serum concentration of Raltegravir. Raltegravir may decrease the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Fosamprenavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Fosamprenavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Fosamprenavir may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Fosamprenavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Fosamprenavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F174251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Management:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral suspension: Administer without food to adults or with food to pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Administer with food if taken with ritonavir. May be administered without regard to food if not taken with ritonavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Serum concentration may be decreased by St John's wort. Management: Avoid St John's wort; concurrent use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. It is not known if fosamprenavir crosses the human placenta. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk. The DHHS Perinatal HIV Guidelines note there are insufficient data to recommend use during pregnancy; however, if used, they recommend that fosamprenavir be given with low-dose ritonavir boosting.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F174240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F174241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be taken with or without food. Adults should take oral suspension",
"     <b>",
"      without",
"     </b>",
"     food; however, children should take oral suspension",
"     <b>",
"      with",
"     </b>",
"     food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F174238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Lexiva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (225 mL): $159.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lexiva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     700 mg (60): $1044.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5067437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor viral load, CD4 count, glucose; triglycerides and cholesterol (prior to initiation and periodically during therapy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F174242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lexiva (IL);",
"     </li>",
"     <li>",
"      Telzer (MX);",
"     </li>",
"     <li>",
"      Telzir (AR, AT, AU, BB, BE, BG, BM, BS, CH, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, GY, HN, IE, IT, JM, MT, NI, NL, NO, PA, PE, PL, PR, PT, RU, SE, SK, SV, TR, TT, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosamprenavir is rapidly and almost completely converted to amprenavir by cellular phosphatases",
"     <i>",
"      in vivo",
"     </i>",
"     . Amprenavir binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 63%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: ~90% (to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein); decreased in hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Fosamprenavir is rapidly and almost completely converted to amprenavir by cellular phosphatases in gut epithelium; amprenavir is hepatically metabolized via CYP isoenzymes (primarily CYP3A4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Not established; food does not have a significant effect on absorption of tablets. Administration of oral suspension with food reduced C",
"     <sub>",
"      max",
"     </sub>",
"     by 46% and AUC by 28%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~7.7 hours (amprenavir)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1.5-4 hours (median: 2.5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (75% as metabolites, &lt;1% as unchanged drug); urine (14% as metabolites, ~1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falcoz C, Jenkins JM, Bye C, et al, &ldquo;Pharmacokinetics of GW433908, A Prodrug of Amprenavir, in Healthy Male Volunteers,&rdquo;",
"      <i>",
"       Clin Pharmacol",
"      </i>",
"      , 2002, 42(8):887-98.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kodoth S, Bakshi S, Scimeca P, et al, &ldquo;Possible Linkage of Amprenavir With Intracranial Bleeding in an HIV-Infected Hemophiliac,&rdquo;",
"      <i>",
"       AIDS Patient Care STDS",
"      </i>",
"      , 2001, 15(7):347-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/11/44217/abstract-text/11483161/pubmed\" id=\"11483161\" target=\"_blank\">",
"        11483161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8634 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44217=[""].join("\n");
var outline_f43_11_44217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174273\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174258\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062602\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062882\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174259\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174260\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174232\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5944477\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174220\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5075151\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174233\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174278\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174271\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174236\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174223\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174227\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174251\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174229\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174239\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174263\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174240\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174241\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174238\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5067437\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174242\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174222\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174235\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8634|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/5/32853?source=related_link\">",
"      Fosamprenavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/28/36297?source=related_link\">",
"      Fosamprenavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_11_44218="Thumb spica cast 1";
var content_f43_11_44218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74904%7EEM%2F60347%7EEM%2F69030%7EEM%2F80982%7EEM%2F59780%7EEM%2F70527%7EEM%2F50574%7EEM%2F61312%7EEM%2F74550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74904%7EEM%2F60347%7EEM%2F69030%7EEM%2F80982%7EEM%2F59780%7EEM%2F70527%7EEM%2F50574%7EEM%2F61312%7EEM%2F74550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First, place a piece of stockinette or similar material over the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Place a stockinette or similar material over the hand and forearm. Minimize wrinkles as much as possible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cut a hole in the stockinette for the thumb. Cut the distal part of the stockinette covering the fingers at about the level of the proximal interphalangeal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After placing the covered thumb through the hole in the stockinette, be sure all the material is as smooth as possible before beginning to apply the webril or other synthetic cast underpadding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extend the underlayment to or just beyond the metacarpophalangeal joints such that there will be adequate padding at the rim of the cast once the underlayment is folded. Wrap the the forearm, hand, and thumb in webril or similar material. Try to make the wrap as smooth and evenly distributed as possible. Wrap the webril so each layer overlaps the previous layer by about three-fourths of its width. Additional material may be needed over bony prominences.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once the stockinette and webril are in place, begin to apply the casting material. Fiberglass cast tape is applied in the photograph above. Apply the tape so each layer overlaps the previous one by about half the width of the material. Be sure to leave the ends of the stockinette extended until you are ready to apply the final layers of casting material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 7",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Before applying the final layer of casting material, fold back the ends of the stockinette. The cast underlayment should roll over the edge of the cast material providing cushioning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 8",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once the stockinette ends are folded back, apply a final layer of casting material. Approximately three layers of fiberglass casting material is sufficient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Final appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photograph above depicts the proper position for the hand and thumb in a completed thumb spica cast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44218=[""].join("\n");
var outline_f43_11_44218=null;
var title_f43_11_44219="Findings child vasculitis";
var content_f43_11_44219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common manifestations of childhood vasculitis at presentation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Involved organ or system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptom or sign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional",
"       </td>",
"       <td>",
"        Fever, weight loss, weakness, fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal",
"       </td>",
"       <td>",
"        Arthralgia, myalgia, arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous",
"       </td>",
"       <td>",
"        Palpable purpura, nodules, urticaria, livedoreticularis, superficial phlebitis, ischemic lesions, mucositis, oral/nasal/genital ulcers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic",
"       </td>",
"       <td>",
"        Headache, stroke, mononeuritis multiplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck",
"       </td>",
"       <td>",
"        Sinusitis, chondritis, otitis, iritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal",
"       </td>",
"       <td>",
"        Nephritis, infarction, hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary",
"       </td>",
"       <td>",
"        Hemorrhage, cavities, nodules, infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td>",
"        Chest pain, heart failure, limb claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        Abdominal pain, mesenteric ischemia, gastrointestinal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory",
"       </td>",
"       <td>",
"        Anemia, elevated erythrocyte sedimentation rate, abnormal liver function tests, hematuria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from: Churg A, Churg J. Systemic Vasculitides. Igaku-Shoin Medical Publishers. New York 1991. Copyright &copy; 1991 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44219=[""].join("\n");
var outline_f43_11_44219=null;
var title_f43_11_44220="Oral and systemic health";
var content_f43_11_44220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Controversial associations between oral and systemic health",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Association",
"       </td>",
"       <td class=\"subtitle1\">",
"        Background",
"       </td>",
"       <td class=\"subtitle1\">",
"        Current status/advice for patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dental amalgam (mercury) and systemic disorders",
"       </td>",
"       <td>",
"        Anecdotes have implicated the mercury in dental amalgam in many systemic illnesses. No data support other than an occasional allergy. Environmental disposal of scrap amalgam is the main issue in trying to reduce its use.",
"       </td>",
"       <td>",
"        Dental amalgam is safe. Removal of mercury-containing fillings should not be done routinely.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic fluoride and systemic disorder",
"       </td>",
"       <td>",
"        Antifluoridationists contend fluoride causes cancer and other ailments. No data support this contention, but voluminous irrefutable data confirm its anticaries benefit.",
"       </td>",
"       <td>",
"        Fluoride remains the single most important anticaries tool available. Today, overuse of fluoride is possible, causing fluorosis, so prescribing needs to follow guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxicity of resins and hormonal interaction",
"       </td>",
"       <td>",
"        Composite resins are used for sealants and tooth-colored fillings. Some chemical components have been suggested as toxic or hormonal analogues. No human or animal studies support these claims, and only trace amounts leak from resins.",
"       </td>",
"       <td>",
"        Resin restorations and dental sealants remain safe for children. Bisphenol-A (BPA)-free sealants are available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthodontic problems and mouth breathing",
"       </td>",
"       <td>",
"        This longstanding controversy holds that certain malocclusions arise from excessive tonsil/adenoid tissue, forcing mouth breathing. T&amp;A procedures can help some children, but not all.",
"       </td>",
"       <td>",
"        Orthodontic malocclusion should not be rationale alone for T&amp;A procedures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal periodontal disease and prematurity of offspring",
"       </td>",
"       <td>",
"        Several independent reports show a strong relationship between mother's gum disease and her likelihood of giving birth prematurely to a low-birth-weight child. Causality is not established, but fetal exposure to periodontal toxins may be a factor.",
"       </td>",
"       <td>",
"        Encourage mothers to establish and maintain personal oral health because dental caries susceptibility is also known to be transmitted by high-caries-risk mothers to offspring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periodontal status and coronary heart disease risk",
"       </td>",
"       <td>",
"        Several independent reports have shown an association between periodontal disease and cardiac disease. Research is looking at circulating proteins. Causality is not established.",
"       </td>",
"       <td>",
"        This does not relate to children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dental caries and lead exposure",
"       </td>",
"       <td>",
"        Recent investigations show a relationship between dental caries and exposure to lead (pica), primarily in poor children.",
"       </td>",
"       <td>",
"        Poverty brings with it health problems, and at this time, this may be simply a covariable associated with being poor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cone beam CT scans and dental diagnosis",
"       </td>",
"       <td>",
"        The use of cone beam computerized tomography (CBCT) is increasing in dentistry, with few data to support its benefit over lower-radiation imaging. In some cases, such as orthognathic surgery, CBCT may offer better diagnostic images.",
"       </td>",
"       <td>",
"        Question dentists on radiation dose and need for CBCT for routine dental treatment.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Casamassimo PS. Pediatr Clin North Am 2000; 47:1149. Copyright &copy; 2000 W.B. Saunders Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44220=[""].join("\n");
var outline_f43_11_44220=null;
var title_f43_11_44221="MF prognosis";
var content_f43_11_44221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides: Impact of skin involvement (T stage) on survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actuarial survival of 543 patients with MF managed at Stanford University. All patients had disease apparently limited to the skin. Survival is calculated from the date of referral to Stanford. 1:140 patients with limited patch/plaque disease (T1, clinical stage IA); 2: 219 patients with generalized patch/plaque disease (T2, clinical stage IB/IIA); 3: 108 patients with tumorous disease (T3, clinical stage IIB0; and 4 : 76 patients with erythroderma (T4, clinical stage III).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Kim, YH, Hoppe, RT. Mycosis fungoides and S&eacute;zary Syndrome. Semin Oncol 1999; 26:276. figure 1, page 279.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44221=[""].join("\n");
var outline_f43_11_44221=null;
var title_f43_11_44222="Evaluation viable myocardium";
var content_f43_11_44222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Indications for intervention and investigative strategy in patients with viable myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Marwick TH. Lancet 1998; 351:815.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44222=[""].join("\n");
var outline_f43_11_44222=null;
var title_f43_11_44223="Amyloidosis of small bowel UGI";
var content_f43_11_44223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper gastrointestinal series showing nonspecific dilatation of small bowel loops (thin arrow) with a stricture in the duodenal loop (thick arrow) in a patient with secondary amyloidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Malagelada JR, Camilleri M, Stanghellini V. Manometric Diagnosis of Gastrointestinal Motility Disorders. Thieme Medical Publishers, New York 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_11_44223=[""].join("\n");
var outline_f43_11_44223=null;
